

Irina Velikyan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/150888/publications.pdf>

Version: 2024-02-01

65
papers

2,213
citations

279798

23
h-index

233421

45
g-index

68
all docs

68
docs citations

68
times ranked

2377
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective of ⁶⁸ Ga-Radiopharmaceutical Development. <i>Theranostics</i> , 2014, 4, 47-80.	10.0	265
2	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸ Ga]ABY-025 Affibody PET/CT. <i>Theranostics</i> , 2016, 6, 262-271.	10.0	204
3	⁶⁸ Ga-Based Radiopharmaceuticals: Production and Application Relationship. <i>Molecules</i> , 2015, 20, 12913-12943.	3.8	179
4	Quantitative and Qualitative Inpatient Comparison of ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-DOTATATE: Net Uptake Rate for Accurate Quantification. <i>Journal of Nuclear Medicine</i> , 2014, 55, 204-210.	5.0	135
5	In vivo binding of [⁶⁸ Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours – impact of peptide mass. <i>Nuclear Medicine and Biology</i> , 2010, 37, 265-275.	0.6	122
6	Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. <i>Cell Metabolism</i> , 2022, 34, 59-74.e10.	16.2	92
7	Preparation and evaluation of (⁶⁸ Ga)-DOTA-hEGF for visualization of EGFR expression in malignant tumors. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1881-8.	5.0	90
8	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule ⁶⁸ Ga-ABY-025 in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 867-871.	5.0	88
9	Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management. <i>Theranostics</i> , 2012, 2, 424-426.	10.0	64
10	Continued rapid growth in ⁶⁸ Ga applications: update 2013 to June 2014. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 99-121.	1.0	57
11	The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a ⁶⁸ Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin. <i>Molecules</i> , 2014, 19, 10455-10472.	3.8	55
12	Positron Emitting [⁶⁸ Ga]Ga-Based Imaging Agents: Chemistry and Diversity. <i>Medicinal Chemistry</i> , 2011, 7, 345-379.	1.5	53
13	The effect of macrocyclic chelators on the targeting properties of the ⁶⁸ Ga-labeled gastrin releasing peptide receptor antagonist PEG 2 -RM26. <i>Nuclear Medicine and Biology</i> , 2015, 42, 446-454.	0.6	46
14	Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. <i>Pharmaceuticals</i> , 2017, 10, 30.	3.8	44
15	Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1337-1346.	6.4	39
16	Prospective of ⁶⁸ Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-24.	0.8	33
17	Theranostic Approach in Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, e410-e420.	1.3	31
18	Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. <i>Theranostics</i> , 2020, 10, 437-461.	10.0	29

#	ARTICLE	IF	CITATIONS
19	⁶⁸ Ga-Labeling of Biotin Analogues and their Characterization. <i>Bioconjugate Chemistry</i> , 2009, 20, 1146-1151.	3.6	28
20	Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes. <i>Scientific Reports</i> , 2020, 10, 16758.	3.3	28
21	Pre-clinical evaluation of [⁶⁸ Ga]Ga-DO3A-VS-Cys40-Exendin-4 for imaging of insulinoma. <i>Nuclear Medicine and Biology</i> , 2014, 41, 471-476.	0.6	27
22	Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4. <i>Acta Diabetologica</i> , 2017, 54, 1039-1045.	2.5	27
23	Dosimetry of [(⁶⁸ Ga)Ga-DO3A-VS-Cys(40)-Exendin-4 in rodents, pigs, non-human primates and human - repeated scanning in human is possible. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 259-69.	1.0	25
24	Synthesis and preclinical evaluation of ⁶⁸ Ga-labeled collagelin analogs for imaging and quantification of fibrosis. <i>Nuclear Medicine and Biology</i> , 2014, 41, 728-736.	0.6	24
25	Regularized reconstruction of digital time-of-flight ⁶⁸ Ga-PSMA-11 PET/CT for the detection of recurrent disease in prostate cancer patients. <i>Theranostics</i> , 2019, 9, 3476-3484.	10.0	24
26	Parametric Net Influx Rate Images of ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast. <i>Journal of Nuclear Medicine</i> , 2017, 58, 744-749.	5.0	23
27	Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. <i>Nuclear Medicine and Biology</i> , 2012, 39, 628-639.	0.6	21
28	First-in-class positron emission tomography tracer for the glucagon receptor. <i>EJNMMI Research</i> , 2019, 9, 17.	2.5	21
29	Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2020, 61, 217-221.	5.0	20
30	In Vivo Instability of ¹⁷⁷ Lu-DOTATATE During Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1337-1340.	5.0	17
31	Dosimetry of [(¹⁷⁷ Lu)-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 109-26.	1.0	16
32	Feasibility of (⁶⁸ Ga)-labeled Siglec-9 peptide for the imaging of acute lung inflammation: a pilot study in a porcine model of acute respiratory distress syndrome. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 18-31.	1.0	16
33	Good manufacturing practice production of [(⁶⁸ Ga)Ga-ABY-025 for HER2 specific breast cancer imaging. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 135-53.	1.0	15
34	Diagnostic HER2-binding radiopharmaceutical, [Ga]Ga-ABY-025, for routine clinical use in breast cancer patients. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 9, 12-23.	1.0	15
35	In vitro autoradiography of carcinoembryonic antigen in tissue from patients with colorectal cancer using multifunctional antibody TF2 and (^{67/68} Ga)-labeled haptens by pretargeting. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 141-50.	1.0	13
36	Synthesis and characterization of scVEGF-PEG-[⁶⁸ Ga]NOTA and scVEGF-PEG-[⁶⁸ Ga]DOTA PET tracers. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 685-692.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Preclinical evaluation of a ⁶⁸ Ga-labeled biotin analogue for applications in islet transplantation. Nuclear Medicine and Biology, 2012, 39, 415-421.	0.6	12
38	Quantification of ¹²⁵ I-Cell Mass in Intramuscular Islet Grafts Using Radiolabeled Exendin-4. Transplantation Direct, 2016, 2, e93.	1.6	12
39	⁶⁸ Ga-DOTATOC PET/MRI and ¹¹ C-5-HTP PET/MRI are superior to ⁶⁸ Ga-DOTATOC PET/CT for neuroendocrine tumour imaging. Journal of Neuroendocrinology, 2021, 33, e12981.	2.6	12
40	The Diversity of ⁶⁸ Ga-Based Imaging Agents. Recent Results in Cancer Research, 2013, 194, 101-131.	1.8	11
41	Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates. Scientific Reports, 2019, 9, 14960.	3.3	11
42	Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. EJNMMI Research, 2020, 10, 21.	2.5	11
43	(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer. Pharmaceuticals, 2020, 13, 39.	3.8	10
44	Radiolabelling and positron emission tomography imaging of a high-affinity peptide binder to collagen type 1. Nuclear Medicine and Biology, 2021, 93, 54-62.	0.6	10
45	Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography. Diabetes, 2021, 70, 842-853.	0.6	10
46	Comparison of ⁶⁸ Ga-PSMA-11 PET/CT with ¹¹ C-acetate PET/CT in re-staging of prostate cancer relapse. Scientific Reports, 2020, 10, 4993.	3.3	9
47	Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes. Journal of Nuclear Medicine, 2021, 62, 833-838.	5.0	9
48	Prospective data-driven respiratory gating of [⁶⁸ Ga]Ga-DOTATOC PET/CT. EJNMMI Research, 2021, 11, 33.	2.5	9
49	Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers. Oncotarget, 2017, 8, 65152-65170.	1.8	9
50	Radionuclides for Imaging and Therapy in Oncology. , 2014, , 285-325.		8
51	Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69. Scientific Reports, 2021, 11, 19151.	3.3	8
52	Organ biodistribution of Germanium-68 in rat in the presence and absence of [(⁶⁸ Ga)Ga-DOTA-TOC for the extrapolation to the human organ and whole-body radiation dosimetry. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 154-65.	1.0	8
53	Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured by ⁶⁸ Ga-DOTATOC PET/CT. EJNMMI Research, 2021, 11, 118.	2.5	8
54	Feasibility of Multiple Examinations Using ⁶⁸ Ga-Labelled Collagelin Analogues: Organ Distribution in Rat for Extrapolation to Human Organ and Whole-Body Radiation Dosimetry. Pharmaceuticals, 2016, 9, 31.	3.8	7

#	ARTICLE	IF	CITATIONS
55	PET-CT imaging of pulmonary inflammation using [68Ga]Ga-DOTA-TATE. EJNMMI Research, 2022, 12, 19.	2.5	6
56	Increased Expression of GLP-1R in Proliferating Islets of Men1 Mice is Detectable by [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 /PET. Scientific Reports, 2018, 8, 748.	3.3	5
57	Carbon Flux as a Measure of Prostate Cancer Aggressiveness: [11C]-Acetate PET/CT. International Journal of Medical Sciences, 2020, 17, 214-223.	2.5	5
58	Comparison of 68Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer. European Journal of Hybrid Imaging, 2022, 6, 5.	1.5	5
59	GMP production of [68Ga]Ga-BOT5035 for imaging of liver fibrosis in microdosing phase 0 study. Nuclear Medicine and Biology, 2020, 88-89, 73-85.	0.6	4
60	Automated GMP-Compliant Production of [68Ga]Ga-DO3A-Tuna-2 for PET Microdosing Studies of the Glucagon Receptor in Humans. Pharmaceuticals, 2020, 13, 176.	3.8	4
61	Improved Radiolytic Stability of a 68Ga-labelled Collagelin Analogue for the Imaging of Fibrosis. Pharmaceuticals, 2021, 14, 990.	3.8	3
62	Exploring the GLP-1â€“GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography. BMJ Open Diabetes Research and Care, 2021, 9, e002083.	2.8	2
63	Glucagon Like Peptide-1 receptor imaging in individuals with Type 2 Diabetes. Journal of Nuclear Medicine, 2021, , jnumed.121.262506.	5.0	2
64	Abstract P3-02-06: A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancer. Cancer Research, 2022, 82, P3-02-06-P3-02-06.	0.9	1
65	Non-invasive determination of HER2-expression in metastatic breast cancer by using ⁶⁸Ga-ABY025 PET/CT.. Journal of Clinical Oncology, 2015, 33, 11067-11067.	1.6	0